
Long left to the fringes of the recreational drug culture, psilocybin — the hallucinatory ingredient in “magic mushrooms” — has recently been making inroads as a legitimate (and fast-acting) antidepressant. Research published Dec. 18 in Cancer shows its benefits may extend to people battling cancer, who often experience the added burden of depression. “As an oncologist for many years, I experienced the frustration of not being able to provide cancer care that treats the whole person, not just the tumor,” said study lead author Dr. Manish Agrawal. “This was a small, open-label study and more research needs to be done, but the potential is significant and could have implications for helping millions of patients with cancer who are also struggling with the severe psychological impact of the disease,” he added in a journal news release. Agrawal is CEO of Sunstone Therapies, based in Rockland, Md, which funded the phase 2 trial. In the trial, 30 people with cancer who were experiencing moderate-to-severe depression got a single, 25 milligram dose of synthesized psilocybin. They also received one-on-one sessions with a therapist and group therapy sessions before, during and after the treatment. Key to patient outcomes was the fact that people were prepped for the treatment beforehand and then received the therapy in these small groups of three to four people, researchers said. Sharing the overall… read on > read on >